ATIM-10. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM
Saved in:
Published in | Neuro-oncology (Charlottesville, Va.) Vol. 19; no. suppl_6; p. vi28 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
06.11.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
ISSN: | 1522-8517 1523-5866 |
---|---|
DOI: | 10.1093/neuonc/nox168.106 |